Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004580
Status:
COMPLETED
Last Update Posted:
2009-02-20
First Post:
1999-11-02
Brief Title:
A Study of ABT-378Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
Phase III Study of ABT-378Ritonavir in Protease Inhibitor Experienced HIV-Infected Patients
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if it is safe and effective to give ABT-378ritonavir combination plus nevirapine plus two nucleoside transcriptase inhibitors to HIV-infected patients who previously have taken protease inhibitors This study also examines how the body handles this combination of anti-HIV drugs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| M97-765 | None | None | None |